Serum Institute of India Upbeat About Oxford University's COVID-19 Vaccine Candidate, an Industrial Info Market Brief
Attachment: India Pharma
As human trials for the University of Oxford's COVID-19 candidate vaccine begins in the United Kingdom, Serum Institute of India (SII)--the Indian partner of the university-led global consortium--is gearing up to start producing 4 million-5 million doses of the vaccine, anticipating a positive outcome.
Although there lies a substantial financial risk in producing an unproven vaccine on a large scale, the company wants to create a decent stockpile of 20 million-30 million doses of the vaccine at the targeted launch in October 2020. The production will be then scaled up to 10 million a month in another six months' time.
Developed by Jenner Institute and the Oxford Vaccine Group, the ChAdOx1 vaccine is the fourth COVID-19 candidate in the world to enter clinical trial phase. But what sets it apart from others is the fact that it is aiming at a minimum time to deliver in mass quantities, while the other three candidates will take at least 12 to 18 months to mass-produce the vaccine.
